Oncoclinicas do Brasil Cash Flow Conversion Efficiency
Oncoclinicas do Brasil cash flow conversion efficiency. Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) has a cash flow conversion efficiency ratio of 0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$151.75 Million ≈ $29.78 Million USD) by net assets (R$1.20 Billion ≈ $235.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncoclinicas do Brasil (2013–2024)
Cash flow conversion efficiency of Oncoclinicas do Brasil from 2013 to 2024. This chart illustrates how Oncoclinicas do Brasil's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Oncoclinicas do Brasil for real-time trading data and today's change.
Oncoclinicas do Brasil Cash Flow Conversion Ratio Explained
Oncoclinicas do Brasil cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncoclinicas do Brasil Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoclinicas do Brasil ranked by their cash flow conversion efficiency. Also see market cap of Oncoclinicas do Brasil for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Jabar
JK:BJBR
|
-0.231x |
|
Paninvest Tbk
JK:PNIN
|
0.018x |
|
B’IN Live Co Ltd
TW:6625
|
0.138x |
|
Selvas Ai Inc.
KQ:108860
|
0.009x |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
-0.023x |
|
Mpact Limited
JSE:MPT
|
-0.008x |
|
Eastech Holding Limited
TW:5225
|
0.058x |
|
Cardiol Therapeutics Inc Class A
TO:CRDL
|
-0.292x |
Annual Cash Flow Conversion Efficiency for Oncoclinicas do Brasil (2013–2024)
The table below shows the annual cash flow conversion efficiency of Oncoclinicas do Brasil from 2013 to 2024. Review how much free cash does Oncoclinicas do Brasil generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$3.38 Billion ≈ $663.69 Million |
R$-184.85 Million ≈ $-36.27 Million |
-0.055x | -183.98% |
| 2023-12-31 | R$2.68 Billion ≈ $525.74 Million |
R$-51.56 Million ≈ $-10.12 Million |
-0.019x | +81.35% |
| 2022-12-31 | R$2.63 Billion ≈ $516.54 Million |
R$-271.64 Million ≈ $-53.30 Million |
-0.103x | -2462.19% |
| 2021-12-31 | R$2.30 Billion ≈ $452.27 Million |
R$-9.28 Million ≈ $-1.82 Million |
-0.004x | -102.81% |
| 2020-12-31 | R$681.17 Million ≈ $133.66 Million |
R$97.56 Million ≈ $19.14 Million |
0.143x | -3.16% |
| 2019-12-31 | R$656.37 Million ≈ $128.79 Million |
R$97.08 Million ≈ $19.05 Million |
0.148x | +78.93% |
| 2018-12-31 | R$470.12 Million ≈ $92.25 Million |
R$38.86 Million ≈ $7.62 Million |
0.083x | -85.80% |
| 2017-12-31 | R$232.44 Million ≈ $45.61 Million |
R$135.26 Million ≈ $26.54 Million |
0.582x | +787.30% |
| 2016-12-31 | R$244.56 Million ≈ $47.99 Million |
R$-20.71 Million ≈ $-4.06 Million |
-0.085x | -435.49% |
| 2015-12-31 | R$195.87 Million ≈ $38.43 Million |
R$-3.10 Million ≈ $-607.69K |
-0.016x | -103.88% |
| 2014-12-31 | R$22.77 Million ≈ $4.47 Million |
R$9.29 Million ≈ $1.82 Million |
0.408x | +167.53% |
| 2013-12-31 | R$48.16 Million ≈ $9.45 Million |
R$7.34 Million ≈ $1.44 Million |
0.152x | -- |
About Oncoclinicas do Brasil
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more